135-LB: A Variable Impact of the Wave 1 and Wave 2 Lockdowns of the COVID-19 Pandemic on Glycemic Control—A Longitudinal Analysis of FGM Adult Users From Poland

Abstract

WHO declared COVID19 pandemic in March 2020. In Poland, the particularly severe restrictions related to COVID19 pandemic were implemented during Wave 1. All activities were prohibited except necessary everyday ones. From late May to July 2020 restrictions were gradually lifted. In October 2020, due to Wave 2 of COVID19 pandemic some restrictions were reimplemented, however, their impact on everyday life was smaller than during the Wave 1. The aim of the study was to analyze the impact of different phases of COVID19 pandemic on glycemic control in patients with diabetes using FGM. Longitudinal data of 469 adults aged 18-64 were analyzed. Analyzed time periods were every first 45 days of each quarter of the year 2020. Q1 stands for the first pre-pandemic quarter of 2020, Q2 correspondences to the severe lockdown of Wave 1, Q3 to time of most restrictions lifted, and Q4 to less strict lockdown of Wave 2. Mean glycemic indices are shown in Table 1. In summary, Wave 1 and Wave 2 of COVID19 pandemic had different impact on glycemic control in patients with diabetes. The severe lockdown of the first wave resulted in adults with diabetes in improvement of glycemic indices, particularly TIR. Common findings during both lockdowns were reduction in TBR and lower glycemic variability as compared to the preceding periods. Disclosure J. Hohendorff: Speaker's Bureau; Abbott, Novo Nordisk, Ascensia Diabetes Care, Dexcom, Inc., Bayer Inc. K. Kao: Employee; Abbott Diabetes. L. Brandner: Employee; Abbott Diabetes. M. Malecki: Advisory Panel; Abbott Diabetes. Speaker's Bureau; AstraZeneca, AlfaSigma. Advisory Panel; Novo Nordisk, Lilly, Sanofi. Speaker's Bureau; Merck & Co., Inc. Research Support; Medtronic. Advisory Panel; Dexcom, Inc. Speaker's Bureau; BIOTON S. A., Servier Laboratories, KRKA. Advisory Panel; Bayer Inc.